European Union funded projects
HTx (H2020) Next generation Health Technology Assessment to support patient-centered, societally oriented, real-time decision-making on access and reimbursement for health technologies throughout Europe
15 partners / 11 countries [2019 Jan – 2023 Dec] More information: http://www.htx-h2020.eu/
The overall objective of HTx is to create a framework for next generation Health Technology Assessment that supports patient-centered, societally oriented, real-time decision-making for integrated healthcare throughout Europe. The mission of HTx is to facilitate the development of methodologies to deliver more customized information on the effectiveness and cost-effectiveness of complex and personalised combinations of health technologies. HTx will also provide methods to support personalised treatment advice that will be shared with patients and their physicians. HTx aims to work in close collaboration with the European Network for HTA (EUnetHTA) and its stakeholders to pilot the implementation of these methods in Europe.
In this project, SRI leads a Work Package on transferability and dissemination, with a specific focus on Central and Eastern European countries and the patient community. SRI contributes to 3 further Work Packages.
VITAL (IMI2) Vaccines and infectious diseases in the ageing population
24 partners / 12 countries [2019 Jan – 2023 Dec] More information: www.imi.europa.eu/projects-results/project-factsheets/vital
The VITAL project will map the burden of potentially vaccine-preventable infectious diseases in the elderly, and investigate vaccinations and immunity to infections in the ageing population. The team will also calculate the clinical and economic consequences of possible vaccination strategies in different age and risk groups, and develop educational materials for stakeholders such as healthcare providers. Ultimately, by addressing the challenge of infectious diseases in the elderly, the VITAL project will contribute to better health for the ageing populations, and a reduced burden on healthcare systems.
In this project, SRI contributes to 3 Work Packages and (co)-leads Tasks on patient flow mapping, transferability assessment of disease burden studies and economic models, and on a systematic literature review of educational and training interventions targeting healthcare professionals aiming to motivate for healthy preventive behavior.
HEcoPerMed (H2020) Healthcare- and pharma-economics in support of the International Consortium for Personalised Medicine – ICPerMed
5 partners / 5 countries [2019 Jan – 2021 Dec] More information: http://hecopermed.eu/
The project responds to the demand for economic models that evaluate treatments made possible through innovations in personalised medicine. HEcoPerMed also seeks to identify funding and reimbursement mechanisms that provide financial incentives for the rapid development and uptake of such innovations. HEcoPerMed goes beyond current assessment and payment models in order to serve the need of personalised medicine for more comprehensive cost-effectiveness estimates – incorporating patient and societal perspectives – and for sustainable affordability of cutting-edge health innovations. HEcoPerMed will provide an overview of and guidance on high quality methodological approaches for model-based economic evaluations.
In this project, SRI leads a Work Package on the application of best practice health economic modelling in personalized medicine, and contributes to 4 further Work Packages.
COMED (H2020) Pushing the boundaries of cost and outcome analysis of medical technologies
6 partners / 6 countries [2018 Jan – 2020 Dec] More information: http://www.comedh2020.eu
COMED aims to advance scientific knowledge by improving existing and developing new research streams for cost and outcome analysis of medical devices; and at the same time, to provide immediately applicable policy advice and tools that will enhance the use of economic evidence in decision-making. COMED’s ambition is to develop scientifically rigorous recommendations on what, when and how real-world evidence sources can and should be used for the evaluation of medical devices.
In this project, SRI leads a Work Package on the transferability of medical device HTA and of evidence on uncertainty factors across EU Member States; and will contribute to 7 further Work Packages.
EU-TOPIA (H2020) Towards improved screening for breast, cervical and colorectal cancer in all of Europe
7 partners / 7 countries [2015 Sep – 2020 Aug] More information: http://eu-topia.org/
The overall aim of EU-TOPIA is to improve health outcomes and equity of breast, cervical and colorectal cancer screening programmes in ways that take full account of the different demographical, medical, political, economic and cultural contexts across Europe.
In this project, SRI leads a Work Package on developing road maps with country-specific feasible changes to the three existing cancer screening programs to reach a more optimal screening performance; and contributes to 5 further Work Packages.
SELFIE (H2020) Sustainable integrated care models for multi-morbidity: delivery, financing and performance
8 partners / 8 countries [2015 Sep – 2019 Aug] More information: www.selfie2020.eu
SELFIE aims to develop a taxonomy of promising integrated care programs for persons with multi-morbidity; to provide evidence-based advice on matching financing / payment schemes with adequate incentives to implement integrated care; to provide empirical evidence of the impact of promising integrated care on a wide range of outcomes using Multi-Criteria Decision Analysis; and to develop implementation and change strategies tailored to different care settings and contexts in Europe, especially Central and Eastern Europe (CEE).
In this project, SRI leads a Work Package on the transferability of most promising ICC models, financial incentives, and performance monitoring to CEE; and contributes to 5 further Work Packages.
EQUIPT (FP7) European-study on quantifying utility of investment in protection from tobacco
11 partners / 7 countries [2013 Oct – 2016 Sep] More information: http://www.equipt.eu
EQUIPT brought together expertise from multiple disciplines and provided health care policy makers with bespoke information about the economic and wider returns that investing in evidence-based tobacco control including smoking cessation agendas can generate.
In this project, SRI was leading a Work Package on comparative return of investment analyses, and contributed to 4 further Work Packages.
Other collaborative projects
Pharmaceutical Value (pValue) initiative
[2019-2021] More information: https://www.ajmc.com/contributor/the-university-of-colorado-pharmaceutical-value/2019/05/complimenting-coverage-and-reimbursement-decisions-with-multicriteria-decision-analysis
The University of Colorado Pharmaceutical Value (pValue) initiative, led by Jonathan Campbell, PhD, and with the support of R. Brett McQueen, PhD, and Melanie D. Whittington, PhD, aims to apply and test novel methods for value assessment that encourages stakeholder engagement and promotes value-based decision making. pValue focuses on developing and testing multicriteria decision analysis as a novel method to estimate the value of innovative healthcare therapies. Findings will be compared to traditional assessments of value. The intent of pValue’s work is to promote an evidence-based approach for decision making. pValue includes a world-renowned Steering Committee alongside collaborators from Syreon Research Institute and Real Endpoints.
Development of a methodological guidance to establish an Essential Medicine List in Ukraine 
The project, initiated by USAID Systems for Improved Access to Pharmaceuticals and Services (SIAPS), aimed to provide recommendations on how to establish and operate an Essential Medicine List (EML) in Ukraine. The methodology included desk research on scientific publications and grey literature sources on EMLs and HTA in Ukraine, review of legislation materials, guidelines, draft processes etc., and conducting multi-stakeholder face-to-face interviews with representatives of various stakeholder groups including patient, government and pharmaceutical industry representatives and HTA experts. Key final outputs were a 7-day HTA training, a 4-day SOP training for the professional staff, and the development of SOPs and a detailed Handbook of Operations for the EML Committee and Secretariat to be established.
SRI was the sole scientific partner of USAID involved in the project.
On-the-spot scientific support for newly established Essential Medicine List (EML) Committee and Secretariat members 
This project, initiated by United States Agency for International Development and World Learning, aimed to provide scientific support practice-oriented training for the members of the newly established Essential Medicine List (EML) Committee and Secretariat in Ukraine. The 3x1-week programme included: Scientific support on Health Technology Assessment (HTA) implementation, EML financing mechanism, the adaptation of decision-making strategy on procurement and reimbursement of medicines included into the EML. Specific tasks included on-the-job training of HTA, development of draft strategy on Multi-Criteria Decision Analysis (MCDA) for decision-making and discussions with key representatives of Ministry of Health, Ministry of Economic Development and Ministry of Finance of Ukraine.
SRI was the sole scientific partner involved in the project.